Medically reviewed
Wegovy HD is a GLP-1 receptor agonist approved for chronic weight management (bmi >=30, or >=27 with at least one weight-related comorbidity). Evidence is from FDA prescribing information and peer-reviewed trials.
Wegovy HD is a GLP-1 receptor agonist used for Chronic weight management (BMI >=30, or >=27 with at least one weight-related comorbidity).
Mechanism of action
Last Revised — by Dr. Jane Novak, MD, MPH
Medically reviewed by Dr. Jane Novak, MD, MPH 8 min read Fact checked Editorial integrityUpdated Jun 6, 2026Pick your plan tier + deductible status for a tier-average estimate. Tap to expand.
Check Wegovy HD against another medication
Already taking something else? Look up interactions.
Type a medication you currently take. We'll route you to the full interaction report — and you should still confirm with your prescriber before changing anything.
Powered by FDA prescribing information cross-references. Not medical advice — for anything serious, call your prescriber or 911.
This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.
Why is Wegovy HD prescribed?
Wegovy HD is FDA-approved to treat:
- Chronic weight management (BMI >=30, or >=27 with at least one weight-related comorbidity)
How it works
7.2 mg is the higher-dose maintenance step approved August 2025 for patients who tolerate 2.4 mg but need additional weight-loss benefit. Same active ingredient (semaglutide) as Wegovy 2.4 mg, three-fold higher weekly dose at maintenance.
“Wegovy HD works by mimicking a natural hormone — the result is slower digestion, reduced appetite, and better blood-sugar control. What matters most is how patients respond over months, not days.”
Dosing schedule
FDA-label titration timeline for Wegovy HD. Doses ramp gradually to limit gastrointestinal side effects; never accelerate the schedule without prescriber input.
Step 1
1-4
0.25 mg
Step 2
5-8
0.5 mg
Step 3
9-12
1.0 mg
Step 4
13-16
1.7 mg
Step 5
17-20
2.4 mg
Step 6
21-24
4.0 mg
Step 7
25+
7.2 mg
Maintenance
Source: FDA prescribing information. Weekly subcutaneous injection. Dose escalation may be delayed if side effects are intolerable. Doses listed here are typical; your prescriber may adjust based on tolerance and response.
Titration schedule
Weekly dose progression
Each escalation holds 4 weeks before the next step up — standard pattern across GLP-1 weight-management labels.
Other reported reactions
Use & safety
Pregnancy
Discontinue >=2 months before planned pregnancy
Breastfeeding
Avoid, secretion into human milk unknown
Missed dose
If missed by <=5 days, inject as soon as possible. If missed by >5 days, skip and resume next scheduled dose.
Storage
Refrigerate 2-8 C unopened. After first use: room temp up to 28 days.
More on Wegovy HD
Reader reviews
Verified user experiences with Wegovy HD. Reviews are moderated before publishing.
No user reviews yet
Be the first to share what worked — side effects, titration experience, dosing, weight-loss timeline. The form below takes ~2 minutes.
Sources & further reading
All clinical claims on this page are sourced from the FDA prescribing information and peer-reviewed literature. Verify the most current label before clinical decisions.
Related medications
Other drugs in the same class — GLP-1 receptor agonist.
Side-effect timeline
peaks fade
Typical 16-week titration schedule. Individual experience varies — track yours with the printable tracker.
- 1
Wk 1-2
First injection
- NauseaModerate
- FatigueModerate
- BloatingMild
Peak nausea — eat small protein-forward meals; hydrate.
- 2
Wk 3-4
Body adapting
- NauseaMild
- ConstipationModerate
- RefluxMild
Constipation climbs as GI motility slows. Add fiber + magnesium.
- 3
Wk 5-8
Dose escalation #1
- NauseaModerate
- FatigueMild
- DiarrheaMild
Symptoms re-spike for ~7 days after each escalation.
- 4
Wk 9-12
Settling in
- NauseaMild
- RefluxMild
GI complaints meaningfully fade. Weight loss accelerates.
- 5
Wk 13-16
Maintenance ramp
- Mild fatigueMild
- Hair sheddingMild
Hair shedding from rapid weight loss may appear (resolves by month 6).
- 6
Wk 17+
Maintenance
- Generally well-toleratedNone
Most side effects resolved. Watch for gallbladder symptoms long-term.
Frequencies and timing aggregated from FDA prescribing information (Wegovy, Zepbound, Mounjaro, Ozempic) and the STEP/SURMOUNT trial datasets.
Was this page helpful?